Quantum Biopharma (NASDAQ:QNTM) Stock Rating Lowered by Wall Street Zen

Quantum Biopharma (NASDAQ:QNTM – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Saturday.

Separately, Weiss Ratings downgraded shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Quantum Biopharma currently has an average rating of “Sell”.

Get Quantum Biopharma alerts:

Check Out Our Latest Research Report on QNTM

Quantum Biopharma Stock Performance

Shares of NASDAQ QNTM opened at $3.24 on Friday. The stock has a market capitalization of $20.74 million, a P/E ratio of -0.39 and a beta of 0.43. The stock’s fifty day moving average is $4.77 and its 200 day moving average is $4.58. Quantum Biopharma has a 52 week low of $2.07 and a 52 week high of $31.91.

Institutional Trading of Quantum Biopharma

Institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC acquired a new stake in Quantum Biopharma in the fourth quarter valued at about $80,000. Virtu Financial LLC bought a new position in Quantum Biopharma in the fourth quarter valued at about $76,000. Finally, Platform Technology Partners acquired a new position in Quantum Biopharma during the first quarter worth about $199,000. 1.24% of the stock is currently owned by institutional investors.

About Quantum Biopharma

(Get Free Report)

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.

Featured Articles

• Five stocks we like better than Quantum Biopharma
• Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
• Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
• Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises
• 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks

Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.